{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:02:54Z","timestamp":1792713774645,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aortic regurgitation (AR) is the third most common valvular heart disease in the Western world. Management of high-surgical-risk patients is challenging. The absence of calcifications in the aortic valve presents anchoring challenges for transcatheter aortic valve implantation (TAVI) in patients with severe native AR.<\/jats:p>\n                    <jats:p>The Trilogy device is a\u00a0dedicated transcatheter heart valve for the treatment of AR and anchors by clipping onto the native aortic valve leaflets. Real-world data comparing dedicated vs. non-dedicated THVs remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated 42\u00a0consecutive high- or prohibitive-surgical-risk patients with pure native AR who underwent transfemoral TAVI. Twenty-one patients received the Trilogy device, and 21\u00a0received non-dedicated transcatheter valves (THV). Co-primary endpoints were device success and early safety at 30\u00a0days. Secondary endpoints included valve embolisation, residual moderate-to-severe AR, new pacemaker implantation, mortality, and length of hospital stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Device success was significantly higher with dedicated THVs (100% vs. 61.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.002). Early safety was comparable (71.4% vs. 61.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.513). There were 4\u00a0valve embolisations (9.5%) and two cardiovascular deaths (4.8%) in the non-dedicated group. Residual moderate-to-severe AR was absent in the dedicated cohort and occurred in 2\u00a0of 21\u00a0non-dedicated cases. Overall, new permanent pacemaker implantation occurred in 19%, with no significant difference between the 2\u00a0cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20091.00). Median hospital stay was significantly shorter in the dedicated cohort (2\u00a0vs.\u00a05 days;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.015).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TAVI with the Trilogy valve system had higher device success as compared to non-dedicated valves and should become the preferred transcatheter strategy for patients with severe native AR at high-operative risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12471-026-02048-4","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:32:39Z","timestamp":1778596359000},"page":"206-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dedicated versus non-dedicated transcatheter valves for pure native aortic regurgitation: a\u00a0single-centre experience"],"prefix":"10.1007","volume":"34","author":[{"given":"Lucas Uchoa","family":"de Assis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antigone","family":"Kostea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio M.","family":"Mondellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M. P.","family":"van den Dorpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kardys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger-Jan","family":"Nuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M.","family":"Van Mieghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2048_CR1","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/heartjnl-2016-310894","volume":"103","author":"P Andell","year":"2017","unstructured":"Andell\u00a0P, Li\u00a0X, Martinsson\u00a0A, et\u00a0al. Epidemiology of valvular heart disease in a\u00a0Swedish nationwide hospital-based register study. Heart. 2017;103:1696\u2013703.","journal-title":"Heart"},{"key":"2048_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","volume":"83","author":"JP Singh","year":"1999","unstructured":"Singh\u00a0JP, Evans\u00a0JC, Levy\u00a0D, et\u00a0al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897\u2013902.","journal-title":"Am J Cardiol"},{"key":"2048_CR3","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1093\/eurheartj\/ehw229","volume":"37","author":"JL d\u2019Arcy","year":"2016","unstructured":"d\u2019Arcy\u00a0JL, Coffey\u00a0S, Loudon\u00a0MA, et\u00a0al. Large-scale community echocardiographic screening reveals a\u00a0major burden of undiagnosed valvular heart disease in older people: the OxVALVE population cohort study. Eur Heart\u00a0J. 2016;37:3515\u201322.","journal-title":"Eur Heart J"},{"key":"2048_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo\u00a0VT, Gardin\u00a0JM, Skelton\u00a0TN, et\u00a0al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005\u201311.","journal-title":"Lancet"},{"key":"2048_CR5","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","volume":"46","author":"F Praz","year":"2025","unstructured":"Praz\u00a0F, Borger\u00a0MA, Lanz\u00a0J, et\u00a0al. ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart\u00a0J. 2025;46:4635\u2013736.","journal-title":"Eur Heart J"},{"key":"2048_CR6","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1016\/j.jacc.2017.10.006","volume":"70","author":"SH Yoon","year":"2017","unstructured":"Yoon\u00a0SH, Schmidt\u00a0T, Bleiziffer\u00a0S, et\u00a0al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J\u00a0Am Coll Cardiol. 2017;70:2752\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"2048_CR7","doi-asserted-by":"publisher","DOI":"10.15420\/icr.2024.37","volume":"20","author":"L Uchoa de Assis","year":"2025","unstructured":"Uchoa de Assis\u00a0L, Mondellini\u00a0GM, van den Dorpel\u00a0MMP, et\u00a0al. Incidence and pathology of aortic regurgitation. Interv Cardiol. 2025;20:e07.","journal-title":"Interv Cardiol"},{"key":"2048_CR8","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.jcin.2023.07.026","volume":"16","author":"E Poletti","year":"2023","unstructured":"Poletti\u00a0E, De Backer\u00a0O, Scotti\u00a0A, et\u00a0al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON International Project. JACC Cardiovasc Interv. 2023;16:1974\u201385.","journal-title":"JACC Cardiovasc Interv"},{"key":"2048_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(23)02806-4","volume":"403","author":"TP Vahl","year":"2024","unstructured":"Vahl\u00a0TP, Thourani\u00a0VH, Makkar\u00a0RR, et\u00a0al. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet. 2024;403:1451\u20139.","journal-title":"Lancet"},{"key":"2048_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","volume":"30","author":"WA Zoghbi","year":"2017","unstructured":"Zoghbi\u00a0WA, Adams\u00a0D, Bonow\u00a0RO, et\u00a0al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J\u00a0Am Soc Echocardiogr. 2017;30:303\u201371.","journal-title":"J Am Soc Echocardiogr"},{"key":"2048_CR11","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","volume":"77","author":"P G\u00e9n\u00e9reux","year":"2021","unstructured":"G\u00e9n\u00e9reux\u00a0P, Piazza\u00a0N, Alu\u00a0MC, et\u00a0al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. J\u00a0Am Coll Cardiol. 2021;77:2717\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"2048_CR12","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/S0140-6736(25)02215-9","volume":"406","author":"RR Makkar","year":"2025","unstructured":"Makkar\u00a0RR, Thourani\u00a0VH, Vahl\u00a0TP, et\u00a0al. Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study. Lancet. 2025;406:2757\u201371.","journal-title":"Lancet"},{"key":"2048_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcin.2024.08.042","volume":"18","author":"S Samimi","year":"2025","unstructured":"Samimi\u00a0S, Hatab\u00a0T, Kharsa\u00a0C, et\u00a0al. Meta-analysis of dedicated vs off-label transcatheter devices for native aortic regurgitation. JACC Cardiovasc Interv. 2025;18:44\u201357.","journal-title":"JACC Cardiovasc Interv"},{"key":"2048_CR14","first-page":"316","volume":"40","author":"S Noble","year":"2024","unstructured":"S\u00a0N, S\u00a0M\u2011W. TAVR as an alternative to SAVR for pure native aortic regurgitation. Can J Cardiol. 2024;40:316\u201325.","journal-title":"Can J Cardiol"},{"key":"2048_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.113.002947","volume":"128","author":"M Barbanti","year":"2013","unstructured":"Barbanti\u00a0M, Yang\u00a0TH, Rod\u00e8s-Cabau\u00a0J, et\u00a0al. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation. 2013;128:244\u201353.","journal-title":"Circulation"},{"key":"2048_CR16","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.jcin.2024.05.019","volume":"17","author":"E Poletti","year":"2024","unstructured":"Poletti\u00a0E, Adam\u00a0M, Wienemann\u00a0H, et\u00a0al. Performance of purpose-built vs off-label transcatheter devices for aortic regurgitation: the PURPOSE Study. JACC Cardiovasc Interv. 2024;17:1597\u2013606.","journal-title":"JACC Cardiovasc Interv"},{"key":"2048_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.shj.2025.100557","volume":"9","author":"D Daniels","year":"2025","unstructured":"Daniels\u00a0D, Vahl\u00a0T, Thourani\u00a0V, et\u00a0al. Novel predictors of new pacemaker implantation and associated outcomes among patients undergoing TAVR for aortic regurgitation in the ALIGN-AR trial. Struct Heart. 2025;9:100557.","journal-title":"Struct Heart"},{"key":"2048_CR18","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.4244\/EIJ-D-24-01117","volume":"21","author":"H Wienemann","year":"2025","unstructured":"Wienemann\u00a0H, Geyer\u00a0M, Stukenberg\u00a0M, et\u00a0al. Predictors of pacemaker implantation in aortic regurgitation patients treated with a\u00a0dedicated transcatheter heart valve. EuroIntervention. 2025;21:e681\u2013e91.","journal-title":"EuroIntervention"},{"key":"2048_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1098348","volume":"10","author":"D Acharya","year":"2023","unstructured":"Acharya\u00a0D, Kazui\u00a0T, Al Rameni\u00a0D, et\u00a0al. Aortic valve disorders and left ventricular assist devices. Front Cardiovasc Med. 2023;10:1098348.","journal-title":"Front Cardiovasc Med"},{"key":"2048_CR20","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.healun.2024.06.018","volume":"43","author":"D Saeed","year":"2024","unstructured":"Saeed\u00a0D, Grinstein\u00a0J, Kremer\u00a0J, Cowger\u00a0JA. Aortic insufficiency in the patient on contemporary durable left ventricular assist device support: a state-of-the-art review on preoperative and postoperative assessment and management. J\u00a0Heart Lung Transplant. 2024;43:1881\u201393.","journal-title":"J Heart Lung Transplant"},{"key":"2048_CR21","first-page":"145","volume":"104","author":"NS Amoroso","year":"2024","unstructured":"Amoroso\u00a0NS, Sharma\u00a0RP, G\u00e9n\u00e9reux\u00a0P, et\u00a0al. Clinical journey for patients with aortic regurgitation: a retrospective observational study from a multicenter database. Catheter Cardiovasc Interv. 2024;104:145\u201354.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2048_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0195-668X(03)00201-X","volume":"24","author":"B Iung","year":"2003","unstructured":"Iung\u00a0B, Baron\u00a0G, Butchart\u00a0EG, et\u00a0al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. Eur Heart\u00a0J. 2003;24:1231\u201343.","journal-title":"Eur Heart J"},{"key":"2048_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/24748706.2021.1988779","volume":"5","author":"VH Thourani","year":"2021","unstructured":"Thourani\u00a0VH, Brennan\u00a0JM, Edelman\u00a0JJ, et\u00a0al. Treatment patterns, disparities, and management strategies impact clinical outcomes in patients with symptomatic severe aortic regurgitation. Struct Heart. 2021;5:608\u201318.","journal-title":"Struct Heart"},{"key":"2048_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/24748706.2020.1846828","volume":"5","author":"S Siddique","year":"2021","unstructured":"Siddique\u00a0S, Vora\u00a0A, Gada\u00a0H. Transcatheter approaches to aortic insufficiency. Struct Heart. 2021;5:55\u201364.","journal-title":"Struct Heart"},{"key":"2048_CR25","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.jcin.2024.06.028","volume":"17","author":"S Garcia","year":"2024","unstructured":"Garcia\u00a0S, Kaneko\u00a0T, Reardon\u00a0M, et\u00a0al. Treatment of aortic regurgitation with a\u00a0novel device: results of the J\u2011Valve early feasibility study. JACC Cardiovasc Interv. 2024;17:2090\u20131.","journal-title":"JACC Cardiovasc Interv"},{"key":"2048_CR26","unstructured":"Rizik DG. Transcatheter treatment of chronic aortic regurgitation with the J\u2011Valve TAVR system: EFS results. Presented at: New York Valves: The Structural Heart Summit; 2025; New York, NY, USA."},{"key":"2048_CR27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jcin.2024.12.006","volume":"18","author":"W Pan","year":"2025","unstructured":"Pan\u00a0W, Chen\u00a0S, Li\u00a0W, et\u00a0al. Early results of multicenter trial of a novel balloon-expandable valve with anchor for aortic regurgitation. JACC Cardiovasc Interv. 2025;18:752\u201364.","journal-title":"JACC Cardiovasc Interv"},{"key":"2048_CR28","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.4244\/EIJ-D-22-00074","volume":"18","author":"Y Feld","year":"2022","unstructured":"Feld\u00a0Y, Yakobi\u00a0D, Hazan\u00a0S, Weigler\u00a0A. Transcatheter aortic valve repair for aortic regurgitation with the Cusper device. EuroIntervention. 2022;18:e179\u2013e80.","journal-title":"EuroIntervention"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-026-02048-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:44:20Z","timestamp":1779889460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-026-02048-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2048"],"URL":"https:\/\/doi.org\/10.1007\/s12471-026-02048-4","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.-J.\u00a0Nuis: Research grant support from Vifor Pharma and Meril and consultancy fees from Edwards Lifesciences, Abbott, and Boston Scientific. J.\u00a0Daemen: Institutional grant\/research support from ACIST Medical, Abbott Vascular, Boston Scientific, Medtronic, Microport, Pie Medical, and ReCor Medical; and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST Medical, Boston Scientific, Cardialysis BV, CardiacBooster, Kaminari Medical, Medtronic, PulseCath, Pie Medical, ReCor Medical, Sanofi, and Siemens Health Care. N.M.\u00a0Van Mieghem: Grant support\/research contracts from Abbott Vascular, Boston Scientific, Medtronic, Edwards Lifesciences, Daiichi Sankyo, AstraZeneca, and PulseCath BV; and consulting\/speaker fees from Abbott Vascular, Boston Scientific Corporation, Medtronic, Daiichi Sankyo, PulseCath BV, JenaValve, and Amgen. L.U.\u00a0de Assis, A.\u00a0Kostea, A.\u00a0Mariani, G.M.\u00a0Mondellini, M.M.\u00a0P.\u00a0van den Dorpel and I.\u00a0Kardys declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}